CoChat

Vaginal microbiota and urinary tract infections in women: the protective role of vaginal lactobacilli in counteracting urinary tract infections occurrence and recurrence

Open access
Francesco Moriconi, Margherita Pelagagge, Marco Bertini · 2026 · infezioni in medicina

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index; 50 of the 114 sources its claims cite were checked for support.

Abstract

Urinary Tract Infections (UTIs) are common clinical conditions.Women are affected by UTIs more than men and their probability of experiencing such conditions is high (60%).The vagina and its defensive system play a key role in the pathogenesis of UTIs, making the vaginal microbiota (VMB) a target for controlling UTIs and their recurrence (rUTIs).Current therapy consists of low-dose antibiotics for rUTIs prevention.The increasing incidence of antimicrobial resistance documented to date has rendered this strategy less attractive.The initial step of UTIs pathogenesis involves colonization of the vaginal introitus and periurethra by uropathogens.The following steps may include the ascension of uropathogens via the urethra to the bladder and kidneys.Vaginal infections may be caused by uropathogens from the intestinal microbiota, taking advantage of the proximity between the anus and the vagina.Nevertheless, uropathogens may arise from the vagina itself because of alterations in VMB.Changes in VMB lead to Bacterial Vaginosis (BV), which consists of the replacement of healthy lactobacilli with unhealthy Gram-negative bacteria, such as Escherichia coli.The documented relationship between BV and UTIs supports the intriguing hypothesis that restoring VMB may represent a new option to control UTIs and rUTIs after short-term antibiotic treatment in a safe and costeffective manner.

Overview

CoChat Summary

## TL;DR

This is a narrative review arguing that vaginal microbiota, especially lactobacilli, play a protective role in women’s urinary tract infections (UTIs) and that restoring a lactobacilli-dominated vaginal ecosystem may help prevent recurrence. It does not report new patient data; instead, it synthesizes prior literature and highlights topical probiotic/symbiotic approaches as promising adjuncts to antibiotics.

## Key findings

  • The paper states that women have a high lifetime probability of UTIs, reported here as 60%, and that recurrence is defined as 3 or more episodes in 1 year or more than 2 in 6 months.
  • It reports that approximately 25% of women with a first UTI develop a second episode, and 25% of those go on to have a third and further recurrence.
  • It notes that E. coli is responsible for 85% of community-acquired UTIs and about 50% of hospital-acquired instances, and that increasing antibiotic resistance is making standard treatment less effective.
  • The review cites clinical studies in which vaginal lactobacilli were associated with reduced recurrences, including a trial of 174 women in which vaginal probiotics with or without oral probiotics outperformed oral probiotics alone, and a study where L. crispatus reduced recurrent cystitis in 86% of patients, with the suppressive effect persisting in 77% for at least a year after therapy ended.
  • It also states that a symbiotic approach using Lactobacillus rhamnosus BMX 54 + lactose had been validated in more than 3000 women with vaginitis/BV and showed statistically significant effectiveness in reducing recurrences.

## Methods

  • Design: Narrative review.
  • Data/sample: Non-systematic literature search in PubMed using keywords related to UTIs, vaginal microbiota, Lactobacillus spp., bacterial vaginosis, and probiotics; English-language articles from 1994 to 2025 were considered, with additional references taken from bibliographies.
  • Analysis: Qualitative synthesis of prior clinical and mechanistic studies; no meta-analysis, no original statistical analysis, and no new patient cohort are reported.

## Limitations

  • The paper explicitly states that the literature it reviews is heterogeneous in study design, methodology, randomization, number of enrolled patients, treatment schedules, and definitions of recurrence.
  • It explicitly says that more specific double-blind randomized controlled studies are required to confirm the conclusions.
  • Evident from the text: because this is a non-systematic narrative review, the conclusions depend on selected prior studies and are not based on a systematic evidence synthesis.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.53854/liim-3401-4

Cites

0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Antibiotic resistance.
Figure 1 Antibiotic resistance.From the PDF
Figure 2 Diagnosis and Management of the common Vaginitis [66].
Figure 2 Diagnosis and Management of the common Vaginitis [66].From the PDF
Image 3
From the PDF
Image 4
From the PDF

Verification

Claims the paper makes

38 Valid · 2 Not valid · 20 Not checked · 6 Own results and interpretations

24 more claims · 14 with their cited sources checked

Create a free account to see all 66 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 18
  • It may state two separate claims as one. 24

Create a free account to see these claims.

Citations

Cites

The publisher hasn’t deposited this paper’s reference list.

Research works printed but not linked: 18

  1. [2][2] Stapleton AE. The Vaginal Microbiota and Urinary Tract Infection. Microbiol Spectr. 2016; 4(6): 1-9.
  2. [4][4] Albert X, Huertas I, Pereiro I, et al. Antibiotics for preventing recurrent urinary tract infection in nonpregnant women (Review). Cochrane Database of Systematic Reviews. 2004; 3: CD001209.
  3. [7][7] Mare ş C, Petca RC, Popescu RI, et al. Update on Urinary Tract Infection Antibiotic Resistance - A Retrospective Study in Females in Conjunction with Clinical Data. Life. 2024; 14: 106.
  4. [10][10] Meštrovi ć T, Matijaši ć M, Peri ć M, et al. The Role of Gut, Vaginal, and Urinary Microbiome in Urinary Tract Infections: From Bench to Bedside. Diagnostics. 2021; 11: 7.
  5. [16][16] Ebell MH. Probiotics Reduce the Likelihood of Recurrence of UTI in Women with Frequent UTIs. Am Fam Physician. 2025; 111(1): 84-85.
  6. [19][19] Pires C. A Systematic Review of Controlled Trials: Can Patient Adherence to Antibiotics Be Improved Through Pharmaceutical Communication-Based Interventions? Pharmacy . 2024; 12: 178.
  7. [20][20] Ghosh R. A Study on the Prevalence of E. coli in the Urinary Tract Infection and the Risk Factors Associated with It. Clinical Microbiology. 2024; 13(3): 1-8.
  8. [21][21] Peralta C, Cortiñas AC, Culaway JM, et al. A Systematic Review on Escherichia coli in Urinary Tract Infections: Prevalence, Resistance Patterns, and Virulence Factors. Int J Innovative Sci Res T ech. 2024; 9(11): 2300-2308.
  9. [24][24] He Y, Zhao J, Wang L, et al. Epidemiological trends and predictions of urinary tract infections in the global burden of disease study 2021. Sci Report. 2025; 15: 4702.
  10. [32][32] Hudson PL, Hung KJ, Bergerat A, et al. Effect of Vaginal Lactobacillus Species on Escherichiacoli Growth. Female Pelvic Med Reconstr Surg. 2020; 26(2): 146-151.
  11. [48][48] Stojanovi ć N, Ple ć aš D, Plešinac S. Normal vaginal flora disorders and application of probiotics in pregnancy. Arch Gynecol Obstet. 2012; 286(2): 325-332.
  12. [49][49] Rossi A, Cattadori F, Corti B. The vaginal ecosystem: how to protect and maintain it. J Obst Prac Gynecol Perinatal Med . 2003; 18: 1.
  13. [52][52] Recine N, Musciola A, Moreira E. The benefits of topical vaginal therapy with Lactobacillus casei subrhamnosus in preventing bacterial vaginosis relapses. Communications and Posters for the X National IBAT Conference 2011, Naples, Italy - January 26-28. 18 (Suppl. 1).
  14. [59][59] Luzi G, Iazzetta E, Cecconi L, et al. Lactobacillus rhamnosus BMX 54 Vaginal application usefulness as adjuvant therapy for Preterm Premature Rupture of Membranes (PPROM) in the second Trimester of Pregnancy. Int J Ped Neonatal Health. 2018; 2(1): 14-20.
  15. [61][61] De Punzio C, Bertini M, Senesi S. Open label pilot study of lactobacillus casei sub-rhamnosus in treating aspecific vaginal diseases. Proceedings from the Italian Society of Gynecology and Obstetrics , Viareggio, 20-24 June, 1999.
  16. [64][64] Bertini M. Is time for thinking to vaginal microbiome to prevent sexually transmitted diseases? Int J Fam Commun Med. 2018; 2: 1.
  17. [65][65] Bertini M. Bacterial vaginosis and sexually transmitted diseases: relationship and management. In: Serdaroglu, S., Kutlubay, Z., editors. Fundamentals of Sexually Transmitted Infections. INTECH Open ; 2017: 75.
  18. [66][66] Friedrich EGJr. Vaginitis. Am J Obstet Gynecol , 1985; 152(3): 247-251.

Cited by

See all 1

Metadata

Authors
Moriconi, F., Pelagagge, M., & Bertini, M.
Affiliations
Baldacci (Italy) (IT)
Venue
infezioni in medicina
Published
2026-03-01
Volume
34
Issue
1
Pages
39-48
ISSN
  • 1124-9390 (ISSN-L)
  • 2532-8689
OpenAlex
W7134074016
Cited by
1
References
0
Citations by year
2026: 1
FWCI
1.15
Type
journal article
Language
en
Open access
Locations
  • Infezioni in Medicina (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion)
Topics
  • Health Sciences › Medicine › Urology › Urinary Tract Infections Management
  • Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
  • Health Sciences › Medicine › Urology › Urinary Bladder and Prostate Research
Keywords
vaginal microbiota, urinary tract infection, recurrent urinary tract infection, vaginal lactobacilli, bacterial vaginosis, Escherichia coli, uropathogens, antimicrobial resistance, women, vaginal microbiota restoration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Vaginal microbiota and urinary tract infections in women: the protective role of vaginal lactobacilli in counteracting urinary tract infections occurrence and recurrence. https://app.cochat.ai/papers/10.53854/liim-3401-4
The paper
Moriconi, F., Pelagagge, M., & Bertini, M. (2026). Vaginal microbiota and urinary tract infections in women: the protective role of vaginal lactobacilli in counteracting urinary tract infections occurrence and recurrence. infezioni in medicina. https://doi.org/10.53854/liim-3401-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.